Abstract | BACKGROUND: METHODS: We evaluated the occurrence of the primary outcome in large cancer groups. The primary outcome was the composite of recurrent VTE or major bleeding over 12 months. RESULTS: In patients with gastrointestinal cancer, the primary outcome occurred in 19.4% patients given edoxaban and in 15.0% given dalteparin (risk difference [RD], 4.4%; 95%-CI, -4.1% to 12.8%). The corresponding rates for edoxaban and dalteparin were 10.4% and 10.7% for lung cancer (RD, -0.3%; 95%-CI, -10.0% to 9.5%), 13.6% and 12.5% for urogenital cancer (RD, 1.1; 95%-CI, -10.1-12.4), 3.1% and 11.7% for breast cancer (RD, -8.6; 95%-CI, -19.3-2.2), 8.9% and 10.9% for hematological malignancies (RD, -2.0; 95%-CI, -13.1-9.1), and 10.4% and 17.4% for gynecological cancer (RD, -7.0; 95%-CI, -19.8-5.7). In the subgroup of gastrointestinal cancer, edoxaban was associated with a 3.5% lower absolute risk of recurrent VTE and a 7.9% higher risk of major bleeding. CONCLUSION:
|
Authors | F I Mulder, N van Es, N Kraaijpoel, M Di Nisio, M Carrier, A Duggal, M Gaddh, D Garcia, M A Grosso, A K Kakkar, M F Mercuri, S Middeldorp, G Royle, A Segers, S Shivakumar, P Verhamme, T Wang, J I Weitz, G Zhang, H R Büller, G Raskob |
Journal | Thrombosis research
(Thromb Res)
Vol. 185
Pg. 13-19
(01 2020)
ISSN: 1879-2472 [Electronic] United States |
PMID | 31733403
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2019. Published by Elsevier Ltd. |
Chemical References |
- Anticoagulants
- Pyridines
- Thiazoles
- edoxaban
|
Topics |
- Anticoagulants
(adverse effects)
- Humans
- Neoplasm Recurrence, Local
- Pyridines
- Thiazoles
(adverse effects)
- Venous Thromboembolism
(drug therapy)
|